Form 4: HCA Healthcare EVP Michael S. Cuffe Sells Shares
SEC Form 4 Filing
Michael S. Cuffe, EVP and Chief Clinical Officer of HCA Healthcare, sold 6,311 shares of common stock at an average price of $316.8792 on May 9, 2024.
Summary
- On May 9, 2024, Michael S. Cuffe, the EVP and Chief Clinical Officer of HCA Healthcare, sold 6,311 shares of HCA common stock.
- The sale was executed at a weighted average price of $316.8792 per share.
- The total shares beneficially owned following the transaction is 29,623.9692.
- The reporting person has undertaken to provide full information regarding the number of shares sold at each separate price within the range of $316.7603 to $317.07 upon request.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating a sale of shares by an executive. The sentiment is neutral as it simply reports a transaction without expressing any positive or negative outlook.
Industry Context
Insider trading activity is always closely watched in the healthcare industry, as it can provide insights into the sentiment of key executives regarding their company's prospects. This sale by an executive is a data point for investors to consider.
Comparison to Industry Standards
- Comparing this transaction to other insider sales within the healthcare sector, it's important to consider the size of the sale relative to Cuffe's total holdings and the overall market capitalization of HCA Healthcare.
- For example, similar sales by executives at Tenet Healthcare (THC) or Universal Health Services (UHS) might be compared based on percentage of holdings sold and the timing relative to earnings announcements or major company events.
- Benchmarking against industry standards involves analyzing the frequency and magnitude of insider transactions across comparable companies to assess whether this sale is an outlier or aligns with typical executive compensation and diversification strategies.
Stakeholder Impact
- The sale of shares by a high-ranking executive could potentially cause concern among shareholders, depending on the context and reasons behind the sale.
- It could also influence employee sentiment, particularly if the sale is perceived negatively.
Key Dates
| Date | Description |
|---|---|
| 2015-02-03 | Date of Power of Attorney execution. |
| 2024-05-09 | Date of stock sale transaction. |
| 2024-05-13 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.